215 results about "Dose" patented technology

The invention discloses a traditional Chinese medicine composition with the effects of benefiting qi, nourishing blood, invigorating the spleen and tonifying the kidney and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: cistanche, ginseng, American ginseng, astragalus membranaceus, medlar, rhizoma polygonati, oyster peptide, angelica sinensis, radix rehmanniae preparata, donkey-hide gelatin, fructus amomi, pericarpium citri reticulatae, hawthorn, folium cortex eucommiae, radix puerariae, liquorice and the like. The preparation method comprises the following steps: respectively crushing the medicinal materials, dissolving the colla corii asini, mixing, adding water, granulating and the like. The composition can be prepared into various dosage forms such as granules, capsules, tablets, oral liquid and the like. Experiments show that the traditional Chinese medicine composition can effectively improve the symptoms of deficiency of qi and blood (increasing erythrocyte count and hemoglobin content), weakness of spleen and stomach (increasing body weight and improving pepsin activity) and kidney deficiency (reducing creatinine and urea nitrogen content and improving SOD activity), and acute toxicity experiments show that the toxicity is slightly reversible under high dosage, and the safety is good under therapeutic dosage. The traditional Chinese medicine composition has potential application value in the aspect of preparing medicines for benefiting qi, nourishing blood, invigorating spleen and tonifying kidney.

Systems, devices and methods are provided for determining a medication dose for a patient or user. The dose determination can account for recent and / or historical analyte levels of the patient or user. The dose determination can also take into account other information about the patient or user, such as physiological information, dietary information, activity, and / or behavior. Many different dose determination embodiments are set forth, pertaining to a wide array of different aspects of the system or environment in which the embodiments can be implemented.

The invention belongs to the technical field of exosome modification, and particularly relates to an exosome modification method for connecting a target protein to the surface of an exosome by utilizing NHS-PEG-NHS to achieve a targeting or treatment effect, and application of the exosome modification method in targeted central nervous system demyelination disease treatment. In particular to a technology for modifying an exosome to enable the exosome to have targeting property and a preparation method of the exosome. NHS-PEG-NHS is used as a connecting substance, and protein, polypeptide and substances with primary amine groups on the surface can be connected to the surface of an exosome membrane. The modified exosome can load drugs and can be accurately delivered to tissues expressing specific proteins or polypeptides through oral administration, so that the bioavailability and the treatment effect of the drugs are remarkably improved. Taking the NG2 antibody modified cow milk exosome as an example, the NG2 antibody is connected to the surface of the cow milk exosome to target the central demyelination focus area, so that the effective therapeutic dose of the drug in the central focus area is achieved through oral delivery.

The invention belongs to the technical field of preparation of probiotics, and provides a bacterial strain with anti-allergic and immunity-improving effects and application of the bacterial strain. According to the method, a three-layer physical self-assembly structure is adopted, and polysaccharide-polyphenol layer-by-layer self-assembly coating treatment, lipid insertion layer treatment and calcium ion crosslinking protection coating treatment are sequentially carried out. And mannan oligosaccharide MOS and / or galactooligosaccharide GOS are / is mixed in the chitosan layer in a ratio of 0.05-0.15% w / v, and the surface sugar ligand density reaches 4-8 [mu] g per 10 CFU. The coating is constructed under the condition that the pH value is 5.4-5.8; the thickness of the lipid layer is 20-80 nm when the pH value is 5.6-6.2; the cross-linked layer is treated at the pH of 6.0-6.5, so that the gastric acid environment is stable for 2 hours, and the gastric acid is controllably released in intestinal juice for 2-4 hours. The prepared strain has the total thickness of 220-900 nm, the outermost layer coverage rate is larger than or equal to 85%, the gastric juice survival rate is remarkably improved, the strain can be prepared into an oral preparation to be used for preventing and relieving allergic diseases, the viable count of each dose is 1 * 10 <-1 > * 10 <-1 > CFU, and the process is mild and suitable for industrial production.

The invention discloses a method and system for analyzing a bacterium-drug interaction panoramic dynamic mechanism by using a causal enlightenment hypergraph neural network, and electronic equipment, and belongs to the technical field of artificial intelligence and biomedical informatics. The method comprises the following steps: constructing a disease / syndrome / disease-bacterium / microorganism / metabolite-prescription / drug / component interlocking hypergraph; analyzing a bacteria-drug interaction dynamic mechanism based on a dynamic hypergraph network algorithm; optimizing the hypergraph neural network based on the prescription compatibility rule and the traditional Chinese medicine dosage; and predicting the microbial marker based on the causal enlightenment hypergraph neural network. According to the method, a multi-entity high-order relation is captured through an interlocking hypergraph structure, a time sliding window and an attenuation mechanism are introduced to analyze dynamic evolution, the traditional Chinese medicine dosage is used as an attention priori optimization network, and causal reasoning is achieved through alternate optimization of an intervention discovery and response prediction module. In a public data set test, the performance evaluation index is obviously superior to that in the prior art, and the problem of analyzing the panoramic dynamic mechanism of the bacterium-drug interaction is effectively solved.

The invention discloses a method for constructing a polycystic ovarian syndrome (PCOS) rat model with reduced sex hormone binding globulin (SHBG) on the basis of ruminococcus aureus with the preservation number of ATCC29149, and belongs to the technical field of animal models. According to the present invention, the bacterial strain is subjected to anaerobic culture to prepare the bacterial liquid, the dosage is 0.2-1 mL / 100 g, the intragastric administration frequency is one time per day to two times per week, and the time lasts for 4-8 weeks, such that the SHBG synthesis of the rat liver is induced to decrease, and the PCOS pathological characteristics such as testosterone level increase, estrus cycle disorder, ovarian polycystic change, insulin resistance and the like are initiated; the problem that a traditional hormone induction method does not conform to the physiological status is solved, the modeling period of a high-fat diet induction method is shortened, and an efficient experimental tool is provided for PCOS mechanism research and drug development.

Compounds and compositions for determining the level of antithrombin (ATIII) in a sample are described along with a system for determining the level of ATIII in a point-of-care setting. Methods of forming the compounds and compositions are also described. Methods of using the compounds and compositions to quantify the level of ATIII in a subject are further described. A system and apparatus are provided that determine the level of ATIII in a point-of-care setting in an efficient manner to facilitate determining a dosage or heparin or ATIII to administer to a patient.

A processor-implemented method comprises obtaining measured glucose values of a person, fitting a physiological model to a portion of the measured glucose values within a time window after a start of a meal to determine meal-specific values of parameters of the physiological model that characterizes the person's glycemic response to the meal, estimating an amount of residual glucose or residual carbohydrate of the meal that would not be counteracted by insulin already delivered to the person using the physiological model and the meal-specific values of the parameters of the physiological model, and determining a dose of a correction bolus to be delivered to the person based on the amount of residual glucose or residual carbohydrate of the meal.

A personalized supplement formulation system integrates biological data, structured qualitative feedback, and machine learning algorithms to generate individualized nutritional protocols. The system receives biological inputs such as genetic single nucleotide polymorphism (SNP) data, blood biomarkers (e.g., ferritin, vitamin D, B12), lipid profiles, and urinary metabolites. A digital user profile is created by organizing these inputs and calculating derived indices relevant to supplementation. Structured qualitative feedback, including dietary restrictions, perceived wellness, and training goals, is normalized and processed alongside the biological data. A trained machine learning engine analyzes combined inputs to output a tailored supplement formulation specifying ingredient selection, dosage, delivery format, and timing. Instructions are transmitted to a manufacturing system capable of producing the custom formulation. The system supports periodic re-evaluation and iteration based on new biological samples or user-reported feedback, enabling dynamic personalization over time and improving efficacy, compliance, and outcome tracking in athletic and wellness domains.

To provide a pharmaceutical composition for treating hypercortisolism in a subject of Cushing's syndrome.SOLUTION: A pharmaceutical composition contains levoketoconazole or a pharmaceutically acceptable salt thereof, and is administered to a subject in need thereof in a therapeutically effective amount. The pharmaceutical composition is administered with a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof. The subject also has type 2 diabetes and has had previous surgery or radiation to treat Cushing's syndrome. The therapeutically effective amount of the pharmaceutical composition is determined via a titration scheme including dose escalation of the pharmaceutical composition. When the subject experiences a dose limitation event, metformin or a pharmaceutically acceptable salt thereof is administered at a dose that is less than the therapeutically effective amount. The dose limitation event is reduction of a fasting blood glucose level, an abnormal renal function, a low vitamin B-12 level or any combination thereof.SELECTED DRAWING: None

The application discloses a point application traditional Chinese medicine composition with an effect of treating irritable bowel syndrome, a point application plaster and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The application provides a point application traditional Chinese medicine composition and a point application plaster. The traditional Chinese medicine composition comprises the following components: psoralea, radix codonopsis, dried zedoary, fried atractylodes, mace, schisandra chinensis and evodia. The composition is prepared according to the principle of less medicine and special function and treatment of disease and seeking the origin. The core tonifying medicine, psoralea, dried zedoary and radix codonopsis, has a prominent dosage proportion and remarkable effects of warming the spleen and kidney yang and invigorating the spleen and replenishing qi. The application finds through clinical research that the clinical total effective rate of the test group is 76.7%, the curative effect is accurate and better than that of a placebo, the IBS-SSS score, the TCM syndrome score and the stool character score of IBS patients can be reduced, the symptoms of the patients are improved, and the composition can effectively treat IBS.

The invention relates to the technical field of information, and discloses a method for predicting the optimal ratio of arginine to lysine in daily ration of lactating sows, and the method comprises the following steps: 1, obtaining historical production data and feed formula data; 2, performing data preprocessing on the historical production data and the feed formula data to obtain historical feature vectors and formula sample data; 3, selecting a preset model with the best performance as a prediction model according to the performance indexes; 4, inputting the to-be-detected feature vector and the crude protein content into the prediction model, and outputting a proportion prediction value of arginine and lysine by the prediction model; 5, performing a field dose response test and acquiring field data; and step 6, inputting the field data into the prediction model, detecting whether data drift occurs in the field data, performing incremental learning when no significant drift occurs in the field data, and performing full-amount learning when significant drift occurs in the field data. The invention further discloses a device for predicting the optimal arginine and lysine ratio of the daily ration of the lactating sows.

The present invention discloses a nutritional care intervention system and method for tumor radiotherapy and chemotherapy patients, belonging to the field of nutritional care intervention. The present invention obtains patient data, obtains patient basic information, treatment plans and constructs a dynamic knowledge base, constructs a nutritional element intake gap model, imports the recommended daily intake and actual intake of nutritional elements of the patient into the nutritional element intake gap model to evaluate the nutritional gap, constructs a drug metabolism and organ tolerance model, imports radiotherapy and chemotherapy drug parameters into the drug metabolism and organ tolerance model to evaluate the drug metabolism situation and organ tolerance dose, constructs a nutritional risk assessment model, and imports the relative nutritional element gap vector, drug metabolism amount, organ tolerance dose, and patient tumor stage into the nutritional risk assessment model to evaluate the patient's nutritional risk. The present invention comprehensively evaluates the patient's nutritional risk based on the patient's nutritional intake situation, drug metabolism process and organ tolerance, and conducts nutritional care intervention on the patient.

To provide a method for treating a proteinuric kidney disease.SOLUTION: There is provided a method comprising administering a predetermined daily dosage of effective amounts of voclosporin over a projected treatment period of at least 24 weeks. The method further comprises: (a) assessing an estimated Glomerular Filtration Rate (eGFR) of a subject at at least a first time point and a second time point on different days within the treatment period; and (b) (i) when the eGFR of the subject decreases by more than a target % to below a predetermined value between the first and second time points, reducing the daily dosage by units of 7.9 mg BID or discontinuing the administration of voclosporin to the subject; (ii) when the eGFR of the subject decreases by less than the target % between the first and second time points, continuing to administer the same predetermined daily dosage of voclosporin to the subject.SELECTED DRAWING: Figure 1

Methods and related compositions using Dichrostachys glomerata to provide a variety of health and wellness benefits in a mammal. More specifically, methods and compositions using Dichrostachys glomerata to reduce anxiety, food cravings, stress and improve mood, physical health, mental health, energy and happiness and improve other quality of life factors in one or more mammals, are provided. In one embodiment, a composition for improving mood in a mammal is provided, wherein the composition comprises an effective amount of Dichrostachys glomerata fruit pods provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

The present disclosure provides a method of administering a low dose soluble protein to a subject in need thereof, wherein the method comprises (a) adding an intravenous solution stabilizer ("IVSS") to an isotonic aqueous solution in a container to form a pretreated container, (b) adding an amount from a protein stock solution to the pretreated container of step (a) to form a low dose protein solution, and (c) administering the low dose protein solution of step (b) to the subject. Optionally, the dose of the soluble protein to be administered to the subject is an ultra-low dose protein, wherein the low dose protein solution undergoes a further dilution step. In particular, the method of administering an ultra-low dose soluble protein comprises: (a) adding an IVSS to an isotonic aqueous solution in a first container to form a first pretreated container, (b) adding an amount from the protein stock solution to the first pretreated container to form a low dose protein solution; (c) adding an IVSS to an isotonic aqueous solution in a second container to form a second pretreated container; and (d) adding an amount of the low dose protein solution in step (b) to the second pretreated container of step (c) to form an ultra-low dose protein solution, and (e) administering the low dose protein solution of step (b) to an individual in need thereof.

The invention discloses application of an aromatic hydrocarbon receptor stimulant in preparation of a medicine for treating diarrhea of weaned piglets and / or inhibiting inflammation, and belongs to the field of biological medicine. According to the present invention, with the PAS-B structural domain of the AHR as the target, the virtual screening technology, the target verification test and the weaned piglet diarrhea pharmacodynamic evaluation test are performed to determine the arctigenin as the AHR strong agonist and the anti-inflammatory drug, and the arctigenin has the good treatment effect on the weaned piglet diarrhea. Experimental results show that 10 mg / kg of arctigenin can significantly relieve diarrhea and hemafecia symptoms of weaned piglets, reduce the content of inflammatory factors in serum and intestinal tissues and improve the intestinal structure of weaned piglets, has no significant cytotoxicity, hepatorenal toxicity and intestinal epithelial cell growth inhibition effect, and can be used for preparing a feed additive for weaned piglets. The compound can be used for preparing medicines for treating diarrhea of weaned piglets. The invention provides a new raw material medicine for treating diarrhea of weaned piglets, and has great economic value and wide application prospect.

This invention relates to the field of medical data-driven dose prediction technology, and discloses a method, system, device, and storage medium for individualized dose prediction of hypothyroidism based on medical data. The method includes: constructing a standardized feature vector based on the child's weight, age in days, corrected age in months, current L-T4 dose, TSH value, FT4 value, previous TSH value, TSH rate of change, feeding method, month of consultation, etiology of hypothyroidism, comorbidity status, previous dose adjustment magnitude, and age at which TSH first reached target levels; extracting TSH dynamic trajectory features from the child's TSH time-series data from previous follow-ups; obtaining a basic recommended dose using a gradient boosting decision tree model constructed with counterfactual filtering training data; and correcting the basic recommended dose to obtain an individualized recommended dose. This method improves the prediction accuracy of the gradient boosting decision tree model and allows the individualized recommended dose to simultaneously take into account multiple clinical confounding factors.

The instant application describes improved methods and compositions for the systemic delivery of therapeutic exosomes to a subject in need thereof. In certain embodiments, the current invention reduces the amount of exosomes delivered to liver, spleen and combinations thereof to allow greater distribution to other areas of the body such as, but not limited to, the brain, pancreas, lung, kidney, muscle. In certain embodiments, the methods involve the injection of one or multiple doses of non-therapeutic exosomes prior to the injection of a suitable therapeutic dose of exosomes with a therapeutic payload. Also included are methods to improve immune clearance of exosomes in subjects by inhibiting phagocytosis.

The invention provides a micro-enema preparation and quantitative evaluation method for improving the quality of a rectum magnetic resonance image, and the method comprises the steps: S2, carrying out a glycerine enema micro-enema operation, squeezing glycerine enema into the rectum, maintaining the operation for a preset time, and recording the defecation frequency and the last defecation character; s3, selecting the dosage of the microenema enema, carrying out grouped experiments by setting a plurality of doses, recording related scores, and selecting the dosage of the enema enema meeting clinical requirements; s4, selecting an on-machine time window before magnetic resonance examination after microenema, performing rectum magnetic resonance examination at a plurality of time nodes after defecation through grouping experiments, observing related scores, and selecting an on-machine time window with a good intestinal tract preparation effect; and S5, carrying out micro-enema adverse reaction evaluation, evaluating a plurality of grades of the subject, calculating an adverse reaction score according to a weighting formula, carrying out clinical decision making, and if the adverse reaction score is lower than a threshold value, terminating the operation and carrying out further processing.

The invention discloses application of a nutritional composition containing alpha-hydroxyisocaproic acid in weight management and blood fat improvement, and belongs to the fields of biological medicine manufacturing, biological medicine application and functional food development. The nutritional composition comprises alpha-hydroxyisocaproic acid and at least one second functional nutritional component, and the second functional nutritional component is preferably selected from one or more of the following components: 1) one or more of tea polyphenol and capsaicin; 2) one or more of beta-glucan, inulin and resistant dextrin; 3) one or more of medium chain triglyceride and sn-1, 3 diglyceride; under the condition of the same intake cycle and dosage, the nutritional composition can significantly improve the weight management effect and reduce related indexes of blood fat through a multi-way synergistic effect, and is combined with GLP-1 drugs or sequentially applied to weight management so as to reduce the risk of weight rise after drug withdrawal.

The present teachings generally include techniques for characterizing the health of an animal (e.g., gastrointestinal health) using image analysis (e.g., of a sample of an exudate such as mucus) as a complement, alternative, or a replacement to traditional laboratory analyses of biological specimens. The present teachings may further include techniques for personalizing a health and wellness plan (including, but not limited to, a dietary supplement such as a customized formula based on a health assessment), where such a plan may be based on one or more of the health characterization techniques described herein. The present teachings may also or instead include techniques or plans for continuous care for an animal, e.g., by executing health characterization and heath planning techniques in a cyclical fashion. A personalized supplement system (e.g., using a personalized supplement, personalized dosing device, and personalized packaging) may also or instead be created using the present teachings.

Techniques for glucose level management are disclosed. In some examples, the techniques may involve obtaining a macronutrient content associated with a meal, wherein the macronutrient content includes a first macronutrient and a second macronutrient. The techniques may further involve predicting, using a patient-specific physiological simulator that utilizes the macronutrient content, glucose amounts to be absorbed into a bloodstream of a patient as a result of consumption of the meal, wherein the patient-specific physiological simulator is configured to account for a difference in glucose level rise due to consumption of the first macronutrient compared to consumption of the second macronutrient. The techniques may further involve determining, using the patient-specific physiological simulator, a dosage of insulin to deliver to the patient based on the glucose amounts to be absorbed into the bloodstream.

Compositions and principles for use before parturition in the prophylactic treatment of hypocalcemia in ruminant animals include compositions having phosphate binders for the prophylactic treatment of parturient hypocalcemia in ruminant animals. These compositions are presented in unit dosage forms, with one or more doses administered daily to the gastrointestinal tract of the ruminant animal, or in wet form. The composition contains one or more phosphate binders and one or more nutrients selected from minerals, vitamins, and amino acids, as well as a composition that includes an inhibitor of the small intestinal Na-phosphate transporter for the prophylactic treatment of parturient hypocalcemia in ruminant animals. Phosphate binders are selected from aluminum, iron, sevelamer, and lanthanum salts, with either inorganic or organic acids, hydrates thereof, or any mixture thereof.

The invention provides an application of an active ingredient targeting miR-365a-3p or a preparation product containing the active ingredient in preparation of a medicine for preventing and treating non-traumatic femoral head necrosis disease. The active ingredient is a medicine composition for dredging arthralgia and generating bone and / or beta-achyransterone. According to the application, experiments prove that the arthralgia-dredging and bone-growing soup and beta-achyranthes bidentata sterone can promote angiogenesis and osteogenesis by improving the expression of miR-365a-3p, so that the arthralgia-dredging and bone-growing soup and the beta-achyranthes bidentata sterone play a positive role in treating NONFH; on a constructed SONFH rabbit model, it is verified that the arthralgia-relieving bone-generating soup can promote bone tissue repair, inhibit fat formation and effectively adjust bone fat metabolism steady state unbalance to achieve bone fat metabolism balance; the optimal dosage of the arthralgia-dredging and bone-generating soup is explored, and it is proved that the arthralgia-dredging and bone-generating soup achieves the effect of regulating and controlling the dynamic balance of the bone fat through a multi-target-point synergistic mechanism of regulating and controlling lipid metabolism, promoting osteogenesis and improving the microenvironment.

The invention discloses an exogenous FSH decreasing injection optimization method for inducing donor cattle superovulation, and relates to the technical field of animal husbandry biological breeding. The method comprises the following steps: acquiring physiological feature data and ovarian reserve function data of donor cattle, constructing an ovarian sensitivity evaluation model and calculating an ovarian sensitivity index; mapping the ovarian sensitivity index into an elimination rate constant, and generating an accumulated blood concentration sequence and a blood concentration metabolism curve according to a superposition principle by combining an injection time point sequence, an injection dosage sequence and a pharmacokinetic parameter table; a multi-target particle swarm optimization algorithm is adopted, follicular development synchronization rate maximization and ovarian over-stimulation risk minimization serve as targets, the fitness is calculated based on a blood concentration metabolism curve, iterative optimization is conducted, and the optimal initial injection dosage and the optimal decline gradient coefficient are output; generating an optimal decline dosing scheme parameter set according to the optimal decline dosing scheme parameter set; while the follicle development consistency and superovulation output are improved, the superovulation treatment stability is improved.

The invention relates to medicine, and more particularly to algology, and can be used in the treatment of pain. The present method includes oral administration of a pharmaceutical composition. Administration begins with a minimum single dose comprising: 1 drop or granule of the composition, dissolved in 15 ml of water, per 10 kg of the patient's weight. The minimum single dose is administered every 15 minutes. An individually tailored single dose is determined by adding up the minimum doses of the composition which induce a subjective sensation of a decrease in pain. The composition is administered in the individually tailored single dose at a dosage frequency of not more than 8 times a day on the first day and not more than four times a day on the second and subsequent days. The pharmaceutical composition contains equal quantities of Eupatorium perfoliatum in a 3D dilution, China officinalis, Secale comutum, Arnica montana in a 3C dilution, Rhus toxicodendron in a 4C dilution, Aconitum napellus, Belladonna, Bryonia alba, Ipecacuanha, Nux vomica in a 5C dilution, Mercurius solubilis in a 6C dilution, Abrotanum, Gallicum acidum, Heloderma suspectum, Senecio aureus in a 7C dilution, and Stramonium in a 9C dilution. The invention provides for a significant decrease in the pain sensations experienced by the patient, irrespective of the source of and reasons for the pain.

The present invention relates to a palatable, free-flowing powdered composition derived from okra (Abelmoschus esculentus) for enhancing endurance. The composition comprises polysaccharides (5-50%), including Rhamnogalacturonan and Arabinogalactan; flavonoid glycosides (2-10%), including Quercetin 3-O-gentiobioside and Isoquercetin (Okraendurosides); and total carbohydrates (30-70%), with optional excipients for stability and bioavailability. The composition on administration to subjects in the appropriate dosage improves running endurance, enhances swimming endurance, improves rate of perceived Exertion (RPE), improves fatigue severity, improves fatigue score, increases peak power and enhances endurance and muscle performance. The invention also discloses a method of preparation involving hydroalcoholic extraction, concentration, and purification, resulting in a water-soluble powder. The composition can be formulated into capsules, tablets, powders, and beverages and is administered orally in doses of 100-2000 mg per day. Animal and human studies confirm its efficacy in enhancing endurance, making it applicable in nutraceutical, sports nutrition, and pharmaceutical industries.

Methods, systems and apparatuses for dose optimization is disclosed. A predetermined threshold may be assigned to a medication. Dose-responses from each subject of a plurality of subjects may be collected and evaluated so that a determination may be made regarding whether a particular dose is equal to a true minimum dose with satisfactory efficacy value.

The invention discloses a colon-targeted Pickering emulsion stabilized by rhein-chitosan composite nanoparticles, a preparation method and an application of the colon-targeted Pickering emulsion. Rhein-chitosan is coupled and then crosslinked with sodium tripolyphosphate to form the rhein-chitosan composite nano-particles, and the nano-particles have better hydrophobicity and acid and alkali resistance stability; the nano-particle suspension and fish oil containing rhein are homogenized and emulsified at a high speed to obtain the Pickering emulsion entrapped with the rhein, and the Pickering emulsion has relatively high rhein drug loading capacity, better stability and good colon-specific release and slow release characteristics; and the traditional Chinese medicine composition has a dose-dependent relieving effect on dextran sodium sulfate induced ulcerative colitis mice, can inhibit inflammatory response and repair intestinal barrier functions, can effectively avoid intestinal nutrition loss caused by rhein, and has a good application prospect.